Upstream & Downstream Processing

PerkinElmer pulls out CGT platform at Biotech Week Boston

PerkinElmer says that its Cellaca PLX system is the cell analysis solution to streamline cell and gene therapy research and production. BioProcess Insider is back at BPI Boston – part of Biotech Week Boston – after three years away where among the many exhibitors PerkinElmer has launched its Cellaca PLX image cytometry system. According to the company, the technology designed by the firm’s Nexcelom unit offers researchers expanded cell sample critical quality attributes (CQA) beyond flow cytometry and staining methods.…

Raw material maker Aceto rebrands as Actylis with eye on $7bn bio space

There is huge demand for customizable raw materials says newly-named Actylis, as it targets further M&A to propel itself into the bioprocess space. In 2019, raw material and ingredient distributor Aceto was acquired by private equity (PE) firm New Mountain Capital. Since then, the firm has moved away from being a virtual supplier via an M&A strategy that has seen seven acquisitions within a two-year period. The acquisitions were: intermediate developers and makers Syntor and IsleChem, large molecule input firm…

Process tech data standards would help biopharma digitize, Siemans study

Drug makers need data standards to realize the full benefits of digital manufacturing tech, according to new analysis. The research – by German technology conglomerate Siemens – focused on how digital systems are reshaping the production of medicines with the authors quizzing executives from 31 firms in the UK and Ireland about changes over the past two years. And the key finding is that biopharmaceutical firms need data standards according to the authors, who cite integration as a major challenge…

Eppendorf upping bioreactor production space in Germany

Steady growth in demand for its bioreactor systems has led Eppendorf to expand its site in Jülich, Germany through the addition of a 3,600 m² facility. The final construction phase of the three-story building began last week, which once operational will more than double production space and increase production capacity by 20% at Eppendorf’s site, located 30km west of Cologne. “The new building offers significantly increased production space for manufacturing bioprocess controllers with the corresponding accessories,” said a spokesperson from…

Terumo BCT launches hollow-fiber perfusion bioreactor for CGT

Terumo Blood and Cell Technologies (BCT) has launched the Quantum Flex Cell Expansion System, saying healthier cells and scalability are among the benefits the bioreactor platform will bring to cell and gene therapy makers. According to the firm, the Quantum Flex system was based on industry’s need for earlier automation to potentially limit additional and time-consuming steps such as bridging studies and technology transfers. Furthermore, the system allows developers to complete early process development on the same platform they will…

Danaher merging Cytiva and Pall to create $7.5bn bioprocess juggernaut

Combining Cytiva and Pall will create the “broadest” and “deepest” bioprocess product portfolio in the industry, says Danaher Corporation. The decision to create ‘The Biotechnology Group’ by merging Danaher’s two bioprocess businesses was announced at the firm’s 2022 Investor & Analyst event last week. Introducing the combined entity, Danaher CEO Rainer Blair told stakeholders the decision represents the third phase in his company’s acquisitional strategy in the bioprocess space, having first acquired and “carved out” the two businesses – Pall…

Thermo Fisher opens $160m MA purification tech plant

As part of a multiyear $650 million CAPEX spend across its bioprocessing business, Thermo Fisher has brought an 85,000 square-foot purification product plant online. The facility in Chelmsford, Massachusetts opened its doors this week, and is set to supply biomanufacturing customers with downstream technologies, specifically for the purification of biologics and vaccines. “This market continues to grow and the world’s leading biopharmaceutical companies depend on our technologies, services and expertise to help deliver life changing therapies to patients,” said Jean…

MilliporeSigma continues SU expansion with €130m France investment

The facility in Molsheim, France will see increased capacity for the manufacturing of MilliporeSigma’s Mobius single-use assemblies and create 800 jobs. The €130 million ($131 million) investment, the largest ever in the 50-year history of the site, will significantly increase capacity for Mobius single-use products within the portfolio of Merck KGaA’s life sciences services business – known as MilliporeSigma in North America. “Molsheim is our largest Life Science campus in France. We have the expertise in-house and the space to…

Vendor identity: Catalent could enter the CDMO elite with Repligen buy

Thermo Fisher branched out from bioprocess vendor to CDMO via M&A so could Catalent do the reverse through a speculative bid to buy Repligen? Earlier this month, rumors emerged that Repligen rejected an unsolicited bid from contract development and manufacturing organization (CDMO) Catalent. According to the StreetInsider, Repligen viewed the offer as being too low, citing a source with knowledge of the matter. Neither Catalent nor Repligen have commented on any rumored bid. But would a merger with Repligen make…

NIIMBL’s Project Call 5.2 looks to address shifting bio-bottlenecks

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) will fund a further 14 projects to address the changing challenges in the biomanufacturing space. Launched in March 2017 as a cooperative agreement with the National Institute for Standards and Technology (NIST), NIIMBL looks to bring industry, academia, and government together to accelerate implementation of advanced biomanufacturing. The Institute’s biannual project calls look to overcome barriers to communication and innovation for biologics technology development, regulatory standards, and workforce development, and the…